替莫唑胺治疗低度非霍奇金淋巴瘤的II期试验。
Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.
作者信息
Woll P J, Crowther D, Johnson P W, Soukop M, Harper P G, Harris M, Brampton M H, Newlands E S
机构信息
CRC Department of Medical Oncology, Christie Hospital, Manchester, UK.
出版信息
Br J Cancer. 1995 Jul;72(1):183-4. doi: 10.1038/bjc.1995.299.
Temozolomide, an imidazotetrazine derivative, was given to 18 patients with low-grade non-Hodgkin's lymphoma (NHL) at a dose of 750 mg m-2 orally, divided over five consecutive days, escalated to 1000 mg m-2 over 5 days (i.e. 200 mg m-2 day-1) if no significant myelosuppression was noted at day 22 of the 28 day cycle. Fifty-six treatment cycles were given to 18 patients. The drug was well tolerated. Only one partial tumour response was documented. The patients were heavily pretreated but had chemoresponsive disease, as shown by a response rate of 69% among 13 patients who went on to receive alternative cytotoxic regimens. We conclude that temozolomide given in this schedule is inactive in previously treated low-grade NHL.
替莫唑胺是一种咪唑并四嗪衍生物，给予18例低度非霍奇金淋巴瘤（NHL）患者，口服剂量为750mg/m²，连续5天给药，若在28天周期的第22天未观察到明显的骨髓抑制，则在5天内将剂量增至1000mg/m²（即200mg/m²/天）。18例患者共接受了56个治疗周期。该药物耐受性良好。仅记录到1例部分肿瘤缓解。这些患者此前接受过大量治疗，但患有化疗反应性疾病，在继续接受其他细胞毒性方案治疗的13例患者中，缓解率为69%。我们得出结论，按此方案给药的替莫唑胺对先前治疗过的低度NHL无效。
Zotero 插件